Vulnerability · Published Dec 1, 2021 · Assigned by icscert

CVE-2020-10627

High 7.3

In plain English

A high-severity improper access control in Omnipod Insulin Management System from Insulet. There are no confirmed reports of exploitation so far. The chance it is exploited in the next 30 days is estimated at 0.5% (higher than 42% of all known vulnerabilities).

Severity (CVSS 3.1)7.3High

Exploit odds (30 days)0.5%top 57.7% of all CVEs

Exploited in the wildNo reportsnot in CISA KEV

Attack toolingNoneno public tooling known

Official description

Insulet Omnipod Insulin Management System insulin pump product ID 19191 and 40160 is designed to communicate using a wireless RF with an Insulet manufactured Personal Diabetes Manager device. This wireless RF communication protocol does not properly implement authentication or authorization. An attacker with access to one of the affected insulin pump models may be able to modify and/or intercept data. This vulnerability could also allow attackers to change pump settings and control insulin delivery.

Affected products (as reported)

Vendor	Product	Versions
Insulet	Omnipod Insulin Management System	1919140160ZXP425ZXR425

Weakness: CWE-284 · Vector: CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:L

References

https://us-cert.cisa.gov/ics/advisories/icsma-20-079-01 x_refsource_MISC
https://www.myomnipod.com/security-bulletins x_refsource_MISC